Trial Profile
A retrospective study evaluating the effectiveness and safety of Certolizumab Pegol in Japanese patients with rheumatoid arthritis in real world
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting